Clinical trials are always on a quest to drive new medicines into the market to improve the health of the diseased. The journey of the cancer clinical trials again experienced the new results. The new drug to treat the bowel caner showed promising results in the clinical trials. Phase III results of the clinical trial demonstrated that the new drug was showing promising results in slowing down tumor growth and extended survival when compared to placebo. With the promising results shown by the drug in phase III, it was un blinded in late 2011. The independent committees of the clinical trial were offered an option to take it as it was showing a significant improvement in the survival of the patients. The drug is yet to seek the approval of FDA. Entry of the bowel cancer drug into market is gives the hope for the survival.
No comments:
Post a Comment